CTIBIOTECH deploys its NAMs in China

CTIBiotech^™, the Lyon-based specialist in 3D-bioprinted human tissue models, has signed a memorandum of understanding and strategic partnership with Beijing Vital River, a Charles River company specialising in research models and preclinical services in China. The aim is to deploy the CRDMO’s preclinical offering in the Chinese market, notably its human tissue-based New Approach Methodologies (NAMs) and proprietary bioassays. The partnership will combine the French specialist’s 3D-bioprinted human tissue models with Beijing Vital River’s preclinical infrastructure. The two companies aim to provide Chinese pharmaceutical and biotechnology players with reproducible models that more closely reflect human physiology, thereby improving the predictive value of preclinical assessments. Signed in Shanghai as part of the Shanghai-Auvergne-Rhône-Alpes Economic Dialogue, the agreement marks a new stage in CTIBiotech’s international expansion, following the opening of its US subsidiary in Philadelphia in May 2026.